E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Chemotherapeutic Agents"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2015)

Special Issue Information

Dear Colleagues,

The journal “Pharmaceuticals” is planning to publish a special issue covering the topic “Chemotherapeutic Agents” and we are inviting you to contribute an article to this volume. Cancer survival has improved drastically in the last four decades. This is the culmination of many factors, most importantly endless work of scientists and clinicians to better understand the pathophysiology of neoplastic cells. Cancer is an extremely heterogeneous disease with several distinct clinical, pathological, genetic, and molecular features. Although significant advances have been accomplished to treat a few cancers such as chronic myelogenous leukemia (CML), acute promyelocytic leukemia (APL), testicular cancer and lymphomas, much more basic, translational and clinical research are needed to fight other hematologic and solid neoplasms. The novel chemotherapeutic agents have revolutionaized our ability to fight cancer. The design and mechanisms of action of the chemotherapeutic agents, their biological activity screening in vitro and in vivo, and subsequent clinical trials are ongoing need of modern industrialized societies. We would like you to share your contributions to the advances and opportunities in this burgeoning field of cancer chemotherapy drug discovery and development for this special issue. Areas of interest include basic and clinical research on novel:

  • Alkylating agents
  • Anti-metabolites
  • Plant alkaloids including vincas, taxanes, podophyllotoxins
  • Topoisomerase inhibitors
  • Kinase signaling pathways and inhibitors
  • Intracellular Redox Modification
  • Targeting Cancer Metabolic Pathways Modulators
  • Monoclonal Antibodies
  • Nanotechnology Drug Delivery
  • Modulators of Tumor Microenvironments
  • Metal- and Metalloid-based Chemotherapy Agents
  • Epigenetic Modifications

Dr. Ashkan Emadi & Dr. Dhimant Desai
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

 


Published Papers (3 papers)

View options order results:
result details:
Displaying articles 1-3
Export citation of selected articles as:

Review

Open AccessReview Glioblastoma Multiforme Therapy and Mechanisms of Resistance
Pharmaceuticals 2013, 6(12), 1475-1506; doi:10.3390/ph6121475
Received: 11 September 2013 / Revised: 4 November 2013 / Accepted: 12 November 2013 / Published: 25 November 2013
Cited by 24 | PDF Full-text (315 KB) | HTML Full-text | XML Full-text
Abstract
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, [...] Read more.
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
Open AccessReview Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes
Pharmaceuticals 2013, 6(11), 1361-1380; doi:10.3390/ph6111361
Received: 12 September 2013 / Revised: 24 October 2013 / Accepted: 28 October 2013 / Published: 4 November 2013
Cited by 21 | PDF Full-text (468 KB) | HTML Full-text | XML Full-text
Abstract
Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, [...] Read more.
Nanomedicine is a growing research field dealing with the creation and manipulation of materials at a nanometer scale for the better treatment, diagnosis and imaging of diseases. In cancer medicine, the use of nanoparticles as drug delivery systems has advanced the bioavailability, in vivo stability, intestinal absorption, solubility, sustained and targeted delivery, and therapeutic effectiveness of several anticancer agents. The expansion of novel nanoparticles for drug delivery is an exciting and challenging research filed, in particular for the delivery of emerging cancer therapies, including small interference RNA (siRNA) and microRNA (miRNAs)-based molecules. In this review, we focus on the currently available drug delivery systems for anticancer agents. In addition, we will discuss the promising use of nanoparticles for novel cancer treatment strategies. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
Open AccessReview Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action
Pharmaceuticals 2013, 6(8), 988-1038; doi:10.3390/ph6080988
Received: 4 June 2013 / Revised: 30 July 2013 / Accepted: 16 August 2013 / Published: 21 August 2013
Cited by 4 | PDF Full-text (1743 KB) | HTML Full-text | XML Full-text
Abstract
The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to [...] Read more.
The use of pharmaceuticals for colon cancer treatment has been increasingly personalized, in part due to the development of new molecular tools. In this review, we discuss the old and new colon cancer chemotherapeutics, and the parameters that have been shown to be predictive of efficacy and safety of these chemotherapeutics. In addition, we discuss how alternate pharmaceuticals have been developed in light of a potential lack of response or resistance to a particular chemotherapeutic. Full article
(This article belongs to the Special Issue Chemotherapeutic Agents)
Figures

Journal Contact

MDPI AG
Pharmaceuticals Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
pharmaceuticals@mdpi.com
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Pharmaceuticals
Back to Top